They should, but instead will pivot to preclinical assets targeting PRAME (at least two other companies are ahead) and CD70 (again, at least two other companies are ahead). They need to communicate a plan for what they're going to look like in the aftermath of this fire sale.
Market Data 
Markets 
AI
